Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of JMT101 + SG001 + irinotecan versus regorafenib in metastatic colorectal cancer
CTR20233283Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug, PBI-1308, irinotecan, regorafenib in colorectal cancer (CRC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Dec 2023; status: active.
02
Drugs
becotatugPBI-1308irinotecanregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20233283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233283.